MXPA05011050A - Uso de b7-h3 como un agente inmunoregulador. - Google Patents

Uso de b7-h3 como un agente inmunoregulador.

Info

Publication number
MXPA05011050A
MXPA05011050A MXPA05011050A MXPA05011050A MXPA05011050A MX PA05011050 A MXPA05011050 A MX PA05011050A MX PA05011050 A MXPA05011050 A MX PA05011050A MX PA05011050 A MXPA05011050 A MX PA05011050A MX PA05011050 A MXPA05011050 A MX PA05011050A
Authority
MX
Mexico
Prior art keywords
modulation
immunoregulatory agent
immunology
vcvc
agonists
Prior art date
Application number
MXPA05011050A
Other languages
English (en)
Spanish (es)
Inventor
Vincent Ling
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA05011050A publication Critical patent/MXPA05011050A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA05011050A 2003-04-17 2004-04-16 Uso de b7-h3 como un agente inmunoregulador. MXPA05011050A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46334203P 2003-04-17 2003-04-17
PCT/US2004/011767 WO2004093894A2 (en) 2003-04-17 2004-04-16 Use of b7-h3 as an immunoregulatory agent

Publications (1)

Publication Number Publication Date
MXPA05011050A true MXPA05011050A (es) 2006-03-17

Family

ID=33310770

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011050A MXPA05011050A (es) 2003-04-17 2004-04-16 Uso de b7-h3 como un agente inmunoregulador.

Country Status (14)

Country Link
US (1) US20050002935A1 (enExample)
EP (1) EP1620119A2 (enExample)
JP (2) JP2006523711A (enExample)
KR (1) KR20060017496A (enExample)
CN (1) CN1809370A (enExample)
AU (1) AU2004231748A1 (enExample)
BR (1) BRPI0409476A (enExample)
CA (1) CA2521847A1 (enExample)
CO (1) CO5700783A2 (enExample)
MX (1) MXPA05011050A (enExample)
NO (1) NO20054790L (enExample)
RU (1) RU2005135739A (enExample)
WO (1) WO2004093894A2 (enExample)
ZA (1) ZA200508367B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500863A (ja) 2000-06-06 2004-01-15 ブリストル−マイヤーズ　スクイブ　カンパニー 免疫調節に有用なｂ７関連核酸およびポリペプチド
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CN1761680A (zh) 2002-12-26 2006-04-19 武田药品工业株式会社 肿瘤迁移抑制素衍生物及其用途
PE20060371A1 (es) 2004-06-25 2006-06-15 Takeda Pharmaceutical Derivados de metastina en el tratamiento del cancer
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
AU2007325872B2 (en) * 2006-11-08 2012-12-13 Macrogenics West, Inc. TES7 and antibodies that bind thereto
NZ705128A (en) 2010-03-04 2015-04-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AU2012248470B2 (en) * 2011-04-25 2016-10-27 Daiichi Sankyo Company, Limited Anti-B7-H3 antibody
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
SG11201606714TA (en) 2014-02-14 2016-09-29 Andrew S Chi Improved methods for the treatment of vascularizing cancers
HK1251475A1 (zh) 2015-10-08 2019-02-01 Macrogenics, Inc. 用於癌症治疗的联合疗法
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
RU2765306C2 (ru) * 2017-03-31 2022-01-28 Цзянсу Хэнжуй Медицин Ко., Лтд. Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение
CN109097366A (zh) * 2017-06-21 2018-12-28 黄海东 突变的人2Ig-B7-H3蛋白编码基因、重组载体、其药物组合物及其应用
US12312406B2 (en) 2018-11-09 2025-05-27 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Anti-B7-H3 antibody, preparation method therefor, conjugate and application thereof
CN112239502B (zh) * 2019-07-18 2024-07-30 泰州复旦张江药业有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CA3124721A1 (en) * 2018-12-24 2020-07-02 Xiaoyi Zhou Recombinant human 21g-b7-h3 protein coding gene, recombinant vector, host cell comprising the same, pharmaceutical composition and use thereof
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技（成都）有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
CN111088227A (zh) * 2019-12-31 2020-05-01 广州航华生物医药科技有限公司 一种细胞分离培养液和t细胞分离培养的方法
CN115279417B (zh) 2021-02-09 2025-01-03 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
CN113144181B (zh) * 2021-04-20 2022-07-19 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
CN118647408A (zh) 2022-02-16 2024-09-13 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
WO2023221975A1 (zh) 2022-05-18 2023-11-23 苏州宜联生物医药有限公司 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
CN120898001A (zh) * 2023-01-10 2025-11-04 上海仁又生基因技术有限公司 重组人2Ig-B7-H3蛋白编码基因、重组载体、宿主细胞、药物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500863A (ja) * 2000-06-06 2004-01-15 ブリストル−マイヤーズ　スクイブ　カンパニー 免疫調節に有用なｂ７関連核酸およびポリペプチド
WO2002010187A1 (en) * 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
EP1423402A4 (en) * 2001-08-02 2006-07-05 Lilly Co Eli NOVEL ANALOGUES OF POLYPEPTIDES AND HYBRID PROTEINS AND METHODS OF USE

Also Published As

Publication number Publication date
WO2004093894A8 (en) 2005-05-19
US20050002935A1 (en) 2005-01-06
CO5700783A2 (es) 2006-11-30
WO2004093894A3 (en) 2005-03-24
BRPI0409476A (pt) 2006-05-02
JP2007191489A (ja) 2007-08-02
CA2521847A1 (en) 2004-11-04
CN1809370A (zh) 2006-07-26
NO20054790D0 (no) 2005-10-18
AU2004231748A1 (en) 2004-11-04
ZA200508367B (en) 2007-04-25
WO2004093894A2 (en) 2004-11-04
NO20054790L (no) 2005-11-16
EP1620119A2 (en) 2006-02-01
RU2005135739A (ru) 2006-03-20
KR20060017496A (ko) 2006-02-23
JP2006523711A (ja) 2006-10-19

Similar Documents

Publication Publication Date Title
MXPA05011050A (es) Uso de b7-h3 como un agente inmunoregulador.
DE60224291D1 (de) System zur antikörperexpression und- synthese
MX342788B (es) Proceso para la concentración de anticuerpos y productos terapéuticos de los mismos.
WO2002074979A3 (en) Expression profiles and methods of use
ATE382690T1 (de) Modulierung der durch cpg-oligonukleotide verursachte immunstimulierung durch positionsbedingte veränderung von nukleosiden
WO2004063342A3 (en) Cellular delivery and activation polypeptide-nucleic acid complexes
ATE494910T1 (de) Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
ATE405650T1 (de) Produktion von ganzen antikörpern in prokaryontischen zellen
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
Eggermont et al. Cytokine‐functionalized synthetic dendritic cells for T cell targeted immunotherapies
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
DE60325611D1 (de) Benzoat- und antranilatinduzierbare promotoren
WO2001059459A3 (en) Compositions and methods for screening therapeutic agents
DE60334466D1 (de) Entkopplung von dna-propagierung und proteinexpression für phagen-display
DE60142861D1 (de) Verwendung von IL-10 Rezeptor beta antagonistische Antikörper zur Hemmung einer IL-TIF/IL-21 Induktion von Akutphasen-Proteine
IL144247A0 (en) Novel odorant receptors in drosophila
DE60139544D1 (de) Veränderte, fluoreszierende proteine
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
BR0309279A (pt) Macromoléculas em multicamadas e métodos para uso das mesmas
WO2003055908A3 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
WO2004046182A3 (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases
WO2004070012A3 (en) Cell-killing molecules and methods of use thereof
DE69836485D1 (de) Hepatitis e-virus aus dem schwein und dessen verwendungen
IL163139A (en) Population based assessments and means to rank the relative immunogenicity of proteins

Legal Events

Date Code Title Description
FA Abandonment or withdrawal